Revenue: As of FY2025, the actual value is USD 303.02 K.EPS: As of FY2025, the actual value is USD -0.0001.EBIT: As of FY2025, the actual value is USD -285.1 K.<h3>Segment Revenue</h3><ul><li>Clinical Trials: Revenue from clinical trials was $301,731 for the year ended May 31, 2025, compared to $213,865 for the year ended May 31, 2024.</li><li>Consulting Fees: Consulting fees were $0 for the year ended May 31, 2025, versus $28,641 for the year ended May 31, 2024.</li><li>Seminar Fees: Seminar fees were $0 for the year ended May 31, 2025, compared to $1,925 for the year ended May 31, 2024.</li><li>Merchandise: Revenue from merchandise was $1,291 for the year ended May 31, 2025, compared to $4,410 for the year ended May 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Gross profit was $262,916 for the year ended May 31, 2025, compared to $203,242 for the year ended May 31, 2024.</li><li>Operating Loss: Operating loss was - $421,365 for the year ended May 31, 2025, compared to - $486,140 for the year ended May 31, 2024.</li><li>Net Loss: Net loss was - $548,820 for the year ended May 31, 2025, compared to - $651,345 for the year ended May 31, 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operations: Net cash used in operations was - $329,627 for the year ended May 31, 2025, compared to - $479,382 for the year ended May 31, 2024.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $341,824 for the year ended May 31, 2025, compared to $471,224 for the year ended May 31, 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Concentration of Revenues: For the year ended May 31, 2025, 66.7% and 24.1% of revenues were received from two customers.</li></ul><h3>Outlook / Guidance</h3>The company anticipates that the introduction of VitaCookies will generate additional revenue and enable it to become profitable in the current fiscal year, provided that expenses remain near current levels. The company hopes to increase revenue and profits by introducing state-of-the-art nanotechnology products, including nanoemulsion-based delivery systems.

Cannabis Bioscience International Holdings, Inc. | 10-K: FY2025 Revenue: USD 303.02 K